Spoken Alpha
Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals develops a software platform to help pharmaceutical companies switch prescription medications to over-the-counter status, including a SaaS component for regulatory compliance and commercialization support and a software-as-medical-device interface for consumer self-selection.
Petros Pharmaceuticals, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $84,744 market cap.
Most recent reported earnings: Q3 FY2025 (Nov 12, 2025).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add PTPI, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PTPI.
$ curl https://api.spokenalpha.com/v1/companies/PTPIFAQ
Spoken Alpha indexes PTPI's earnings call transcripts at https://spokenalpha.com/companies/PTPI. Each call links to attributed speakers and parsed analyst Q&A. Petros Pharmaceuticals, Inc.'s own investor relations page is at https://investors.petrospharma.com/.
Petros Pharmaceuticals, Inc. (PTPI) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2025 | 2025-11-12 | $-0.03 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-1.58 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-8.46 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-1.07 | $-1.31 | +18.3% | $725.4K | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-13.25 | $-7.25 | -82.8% | $1.6M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-9.25 | $-19.25 | +51.9% | $1.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-42.25 | $-36.00 | -17.4% | $1.4M | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-54.25 | $-27.75 | -95.5% | $-364.3K | — | — | EODHD |
| Q3 FY2023 | 2023-11-14 | $-2.31 | — | — | $1.7M | — | — | EODHD |
| Q2 FY2023 | 2023-08-29 | $-30.07 | — | — | $2.0M | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $-16.58 | — | — | $2.5M | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-2.03 | — | — | $798.1K | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.67 | — | — | $-1.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.09 | — | — | $4.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.01 | — | — | $2.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.83 | $0.00 | — | $-867.2K | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.17 | — | — | $2.1M | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.22 | — | — | $2.5M | — | — | EODHD |
| Q1 FY2021 | 2021-05-13 | $0.31 | — | — | $4.1M | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-2.12 | $0.00 | — | $2.9M | — | — | EODHD |
Source: EODHD. PTPI reported actuals as published; sparse fields render as —.